Copyright
©The Author(s) 2016.
World J Nephrol. Sep 6, 2016; 5(5): 471-481
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.471
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.471
Table 1 Baseline patient characteristics (n = 470), as a function of vitamin D status
All | 25(OH)D < 20 ng/mL | 25(OH)D 20-29 ng/mL | 25(OH)D ≥ 30 ng/mL | P | |
n | 470 | 252 (53%) | 154 (33%) | 64 (14%) | |
Age (yr) | 66.1 ± 12.9 | 65.8 ± 13.1 | 65.9 ± 11.9 | 68.1 ± 12.1 | 0.421 |
Male sex (%) | 309 (66%) | 162 (64%) | 101 (66%) | 46 (72%) | 0.303 |
High blood pressure (%) | 444 (95%) | 242 (96%) | 144 (94%) | 58 (91%) | 0.072 |
Dyslipidemia (%) | 311 (66%) | 168 (68%) | 101 (66%) | 42 (66%) | 0.646 |
Diabetes mellitus (%) | 183 (39%) | 114 (45%) | 53 (34%) | 16 (25%) | 0.001 |
Ischemic heart disease (%) | 104 (22%) | 60 (24%) | 33 (22%) | 11 (17%) | 0.224 |
Chronic heart failure (%) | 43 (9%) | 33 (13%) | 7 (5%) | 3 (5%) | 0.005 |
Stroke (%) | 52 (11%) | 30 (12%) | 15 (10%) | 7 (11%) | 0.668 |
Peripheral arterial disease (%) | 93 (20%) | 59 (24%) | 22 (14%) | 12 (19%) | 0.117 |
Stage of CKD (%) | |||||
3 (eGFR = 30-59 mL/min per 1.73 m2) | 221 (47%) | 103 (41%) | 84 (54%) | 34 (53%) | 0.002 |
4 (eGFR = 15-29 mL/min per 1.73 m2) | 205 (44%) | 105 (46%) | 64 (42%) | 26 (41%) | |
5 (eGFR < 15 mL/min per 1.73 m2) | 44 (9%) | 34 (13%) | 6 (4%) | 4 (6%) | |
Etiology of CKD (%) | |||||
Hypertension | 108 (23%) | 54 (21%) | 40 (26%) | 14 (22%) | 0.039 |
Diabetes mellitus | 108 (23%) | 72 (29%) | 29 (19%) | 7 (11%) | |
Tubulointerstitial disease | 65 (14%) | 24 (10%) | 25 (16%) | 16 (25%) | |
Glomerulonephritis | 47 (10%) | 26 (10%) | 15 (10%) | 6 (10%) | |
Unknown/others | 142 (30%) | 75 (30%) | 44 (29%) | 20 (32%) | |
Smoking (%)1 | |||||
Never | 231 (53%) | 124 (52%) | 82 (58%) | 25 (44%) | 0.494 |
Ex-smoker | 144 (33%) | 81 (34%) | 44 (31%) | 19 (33%) | |
Active | 64 (14%) | 35 (14%) | 16 (11%) | 13 (23%) | |
Blood pressure (kPa) | |||||
Systolic | 19.0 ± 2.9 | 19.3 ± 2.9 | 18.6 ± 2.8 | 19.0 ± 3.1 | 0.085 |
Diastolic | 10.2 ± 1.5 | 10.2 ± 1.6 | 10.1 ± 1.4 | 10.3 ± 1.7 | 0.617 |
Pulse pressure (kPa) | 8.8 ± 2.5 | 9.1 ± 2.5 | 8.5 ± 2.5 | 8.7 ± 2.5 | 0.098 |
Body mass index (kg/m2) | 28.6 ± 5.1 | 28.8 ± 5.5 | 28.6 ± 4.6 | 27.7 ± 4.4 | 0.294 |
Underweight ( ≤ 18.5) | 6 (1%) | 4 (2%) | 1 (1%) | 1 (2%) | 0.353 |
Normal (18.6-24.9) | 96 (20%) | 50 (20%) | 30 (19%) | 16 (25%) | |
Overweight (25.0-29.9) | 210 (45%) | 111 (44%) | 68 (44%) | 31 (48%) | |
Obesity (> 29.9) | 158 (34%) | 87 (34%) | 55 (36%) | 16 (25%) | |
Waist (cm) | |||||
Males | 102.2 ± 12.0 | 102.1 ± 13.0 | 102.2 ± 10.6 | 102.4 ± 11.5 | 0.989 |
Females | 97.8 ± 13.5 | 98.3 ± 14.7 | 97.7 ± 12.2 | 95.7 ± 11.4 | 0.760 |
ABPI | 1.01 ± 0.21 | 0.98 ± 0.20 | 1.04 ± 0.21 | 1.05 ± 0.22 | 0.013 |
Abnormal ABPI2 | 194 (41%) | 100 (41%) | 66 (44%) | 28 (44%) | 0.539 |
Abnormal Kauppila score3 | 107 (29%) | 52 (27%) | 35 (29%) | 20 (36%) | 0.183 |
Abnormal Adragao score4 | 121 (32%) | 66 (33%) | 38 (30%) | 17 (29%) | 0.474 |
Vitamin D supplementation (%) | 43 (9%) | 16 (6%) | 17 (11%) | 10 (16%) | 0.012 |
Use of phosphate binders (%) | 72 (15%) | 47 (19%) | 16 (11%) | 9 (14%) | 0.105 |
Use of ACEI/ARB (%) | 365 (78%) | 196 (79%) | 121 (82%) | 48 (76%) | 0.947 |
Use of diuretic (%) | 287 (61%) | 173 (70%) | 88 (58%) | 26 (42%) | < 0.001 |
Use of ESA (%) | 124 (26%) | 77 (31%) | 31 (20%) | 16 (25%) | 0.015 |
Table 2 Baseline laboratory values, as a function of vitamin D status
All (n = 470) | 25(OH)D < 20 ng/mL (n = 252) | 25(OH)D 20-29 ng/mL (n = 154) | 25(OH)D ≥ 30 ng/mL (n = 64) | P | |
25-hydroxivitamin D (nmol/L) | 52 ± 21 | 36 ± 9 | 61 ± 7 | 90 ± 16 | < 0.001 |
1,25(OH)2 vitamin D (pmol/L) | 103 ± 28 | 97 ± 27 | 111 ± 28 | 107 ± 23 | < 0.001 |
Caalb (mmol/L) | 2.40 ± 0.20 | 2.40 ± 0.15 | 2.42 ± 0.23 | 2.45 ± 0.23 | 0.163 |
P (mmol/L) | 1.10 ± 0.26 | 1.10 ± 0.26 | 1.10 ± 0.26 | 1.07 ± 0.26 | 0.517 |
iPTH (ng/L)1 | 91 (85-97) | 106 (96-116) | 81 (73-91) | 64 (55-74) | < 0.001 |
Creatinine (μmol/L) | 221 ± 97 | 239 ± 106 | 212 ± 88 | 212 ± 88 | 0.017 |
eGFR (MDRD, mL/min per 1.73 m2) | 29.4 ± 11.5 | 28.1 ± 11.9 | 30.8 ± 10.8 | 30.5 ± 11.1 | 0.049 |
Urine protein excretion (g/24 h)12 | 0.592 (0.502-0.697) | 0.699 (0.573-0.853) | 0.448 (0.321-0.626) | 0.448 (0.271-0.742) | 0.034 |
hsCRP (nmol/L)1 | 36.2 (29.5-39.1) | 37.1 (33.3-41.0) | 36.2 (31.4-41.0) | 32.4 (26.7-39.1) | 0.506 |
Albumin (g/L) | 40 ± 5 | 39 ± 5 | 41 ± 5 | 40 ± 5 | 0.011 |
Total proteins (g/L) | 77 ± 12 | 77 ± 11 | 77 ± 13 | 76 ± 14 | 0.877 |
Total cholesterol (mmol/L) | 4.7 ± 1.1 | 4.7 ± 1.1 | 4.7 ± 1.0 | 4.8 ± 1.1 | 0.603 |
HDL cholesterol (mmol/L) | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.3 ± 0.4 | 1.3 ± 0.4 | 0.973 |
LDL cholesterol (mmol/L) | 2.7 ± 0.9 | 2.7 ± 0.9 | 2.7 ± 0.9 | 2.9 ± 0.8 | 0.344 |
Hemoglobin (g/L) | 130 ± 16 | 129 ± 16 | 132 ± 16 | 132 ± 18 | 0.058 |
Ferritin (pmol/L)1 | 225 (207-245) | 227 (202-252) | 216 (187-252) | 247 (191-319) | 0.635 |
Transferrin (μmol/L) | 3.0 ± 1.2 | 2.9 ± 1.2 | 3.0 ± 1.2 | 3.1 ± 1.3 | 0.289 |
Glucose (mmol/L) | 6.3 ± 2.2 | 6.3 ± 2.3 | 6.4 ± 2.4 | 5.9 ± 1.5 | 0.241 |
Table 3 Adjusted Cox proportional hazards models of patient survival (events = 46)
Model | Covariates controlled for | Adjusted HR (95%CI) | P |
0 (Unadjusted) | 25-hydroxivitamin D levels (mg/dL) | 0.95 (0.91-0.99) | 0.009 |
1 | 25-hydroxivitamin D levels (mg/dL) + age | 0.95 (0.91-0.99) | 0.009 |
2 | Model 1 + diabetes mellitus, ischemic heart disease, chronic heart failure | 0.96 (0.92-0.99) | 0.028 |
3 | Model 1 + peripheral arterial disease, abnormal ABPI1, phosphorous (mg/dL) | 0.95 (0.92-0.99) | 0.023 |
4 | Model 1 + DBP (mm Hg), 1,25(OH)2 vitamin D (pg/mL), estimated GFR (mL/min per 1.73 m2) | 0.96 (0.92-0.99) | 0.020 |
5 | Model 1 + vascular calcification [Kauppila score (log), Adragao score (log)], CKD stage 5 | 0.95 (0.91-1.00) | 0.050 |
6 | Model 1 + obesity, hemoglobin (g/L), albumin (g/dL) | 0.95 (0.92-0.99) | 0.019 |
Table 4 Multivariate Cox regression analysis in relation to renal end point (events = 156)
HR (95%CI) | P value | |
25-hydroxivitamin D (ng/mL) | 0.97 (0.95-0.99) | 0.004 |
Age (yr) | 0.99 (0.97-1.00) | 0.044 |
Male sex | 2.20 (1.47-3.30) | < 0.001 |
Estimated GFR (mL/min per 1.73 m2) | 0.93 (0.91-0.95) | < 0.001 |
ABPI (mmHg) | 0.23 (0.10-0.53) | 0.001 |
Hemoglobin (g/L) | 0.84 (0.78-0.94) | 0.001 |
- Citation: Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol 2016; 5(5): 471-481
- URL: https://www.wjgnet.com/2220-6124/full/v5/i5/471.htm
- DOI: https://dx.doi.org/10.5527/wjn.v5.i5.471